Custom-Made vaccine takes on kidney cancer in early trial
Disease control
Ongoing
This early-phase study tests a personalized vaccine made from each patient's unique tumor mutations, combined with the immunotherapy drug ipilimumab, for people with high-risk kidney cancer. The goal is to see if the treatment is safe and can boost the immune system to fight the …
Phase: PHASE1 • Sponsor: Patrick Ott, MD, PhD • Aim: Disease control
Last updated May 14, 2026 12:05 UTC